SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2015
Prana Biotechnology Limited
(Name of Registrant)
Level 2, 369 Royal Parade Parkville Victoria 3052 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):__
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____
This Form 6-K is being incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-199783) and Form S-8 (File No. 333-153669).
PRANA BIOTECHNOLOGY LIMITED
| 6-K | Items |
| 1. | Response to ASX Price Query |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PRANA BIOTECHNOLOGY LIMITED | |||
| (Registrant) | |||
| By: | /s/ Geoffrey Kempler | ||
| Geoffrey Kempler, | |||
| Executive Chairman | |||
May 21, 2015
Thursday, 21st May 2015
Esmond Prowse
Advisor, Listings Compliance (Melbourne)
ASX Compliance Pty Ltd
Level 4, Rialto North Tower
525 Collins Street
Melbourne VIC 3000
Dear Esmond,
Prana Biotechnology Limited (the “Entity”) – ASX Price Query
We refer to your email received on Thursday 21st May 2015, in relation to a noted increase in the price and increase in trading volume of the Entity’s securities today.
We provide the following response to your queries:
| 1. | Is the Entity aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities? |
No, the Entity is not aware of any information not already released to the market. The Entity has not provided earnings guidance, and does not believe the share price is strongly related to the financial performance of the Entity at this stage.
| 2. | If the answer to question 1 is yes; |
Not applicable.
| 3. | If the answer to question 1 is no, is there any other explanation that the Entity may have for the recent trading in its securities? |
Prana submitted an application to the Committee for Orphan Medicinal Products (COMP), a division of the European Medicines Agency, requesting an orphan medicinal product designation for the use of PBT2 to treat Huntingtons Disease
The COMP recommended the granting of orphan medicinal designation and forwarded its opinion to the European Commission.
The Company announced to the market the COMP’s positive recommendation on 28 April, 2015. The Company has not been notified of the European Commission’s decision. Meanwhile, without notice of timing to the Company, yesterday the EMA published the minutes of the meeting on their website. There is nothing substantively new in the Meeting Minutes that was not disclosed in the Company’s announcement of April 28.
The Entity has no direct explanation for the reasons for the increase in price of the securities.
| 4. | Please confirm that the Entity is in compliance with the Listing Rules and, in particular, Listing Rule 3.1. |
The Entity continues to be in compliance with the Listing Rules including Rule 3.1
Yours faithfully,
Phillip Hains
Company Secretary
Suite 1, 1233 High Street Armadale
Victoria Australia 3143
Telephone: +61 3 9824 5254
Facsimile: +61 3 9822 7735